Canagliflozin

Canagliflozin
	File:Canagliflozin.png
Systematic (IUPAC) name
	(2S,3R,4R,5S,6R)-2-{3-[5-[4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol
Identifiers
CAS Number	842133-18-0
ATC code	none
Synonyms	JNJ-24831754; TA 7284; (1S)-1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol
Chemical data
Formula	C24H25FO5S
Molar mass	444.52 g/mol[[Script error: No such module "String".]]

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Canagliflozin is an experimental drug being developed by Johnson & Johnson for the treatment of type 2 diabetes.^[1] It is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.^[2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

45px	This drug article relating to the gastrointestinal system is a stub. You can help ssf by expanding it. v d e